TAK

Handel nachbörslich: 16.85 -0.06 -0.35%

Takeda Pharmaceutical Co Adr (TAK)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile

Takeda Pharmaceutical Co Adr

Healthcare (1113)

@takedapharma

Nächster Verdiensttermin

Neueste SEC-Einreichungen

TAK's Discussions on Twitter

Vergleichen Sie TAK mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TAK Takeda Pharmaceutical Co Adr	16.91	52.47B	29.63B	260.53M	5.51B	0.0788
ZTS Zoetis Inc	124.96	54.61B	9.40B	2.65B	2.24B	5.935
HLN Haleon Plc Adr	10.42	46.18B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	32.53	36.87B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	476.78	20.38B	3.08B	1.24B	1.07B	25.61

Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-13	Fortgesetzt	Morgan Stanley	Overweight
2025-04-02	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-03-16	Hochstufung	BofA Securities	Neutral → Buy
2022-07-19	Hochstufung	Cowen	Market Perform → Outperform
2021-10-07	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-04-19	Herabstufung	JP Morgan	Overweight → Neutral
2019-11-01	Eingeleitet	Cowen	Market Perform
2019-08-15	Herabstufung	Daiwa Securities	Outperform → Neutral

Alle ansehen

Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten

Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)

Takeda Pharmaceutical Co Adr (TAK)

Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile

Vergleichen Sie TAK mit anderen Aktien

Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades

Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten

Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.

Takeda Pharmaceutical ADR Gets Technical Rating Upgrade - Investor's Business Daily

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

US earnings seasonQ4 2025 - Interactive Investor

Takeda Pharmaceutical ADR: Defensive Pharma Giant Tests Investor Patience as Shares Drift Near Lows - AD HOC NEWS

ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz

KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Finviz

Takeda Pharmaceutical ADR Sees IBD RS Rating Climb To 76 - Investor's Business Daily

Book value per share of Takeda Pharmaceutical Co. Ltd. Sponsored ADR – GETTEX:TKDA - TradingView — Track All Markets

The Truth About Takeda Pharmaceutical Co Ltd: Is This Pharma Giant a Hidden Power Play for Your Port - AD HOC NEWS

G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.

Ethic Inc. Buys 43,295 Shares of Takeda Pharmaceutical Co. $TAK - Defense World

Takeda Pharmaceutical (NYSE:TAK) Strengthens Position in Healthcare - Kalkine Media

Takeda Pharmaceutical Co Ltd (TAK) Bonds - GuruFocus

Takeda Pharmaceutical Co Ltd ADR Stock Price Today | NYSE: TAK Live - Investing.com

Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.

Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz

INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com

TAK vs. DSNKY: Which Stock Is the Better Value Option? - MSN

Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Coca-Cola Upgraded, Boeing Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

ADR movements on the 11th: In yen terms, Kirin HD, Takeda Pharmaceutical, and Mitsui Metals showed gains. - 富途牛牛

Takeda Pharma ADR earnings beat by $278.84, revenue fell short of estimates - Investing.com Nigeria

CMBI Adds INNOVENT BIO (01801.HK) TP to $110.62 on Strategic Partnership with Takeda Pharmaceutical - AASTOCKS.com

BofAS Elevates INNOVENT BIO (01801.HK) TP to $113 as Co-op with Takeda Pharmaceutical Marks Major Step Towards Becoming Multinational Pharma Firm - AASTOCKS.com

CLSA Lifts INNOVENT BIO's TP to HKD120.1; Takeda Pharma Co-op Positive for Product Development - AASTOCKS.com

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Placera.se

INNOVENT BIO Opens Up 10% on Shr Issuance to Takeda Pharma at ~30% Premium w/ Licensing Deal Worth USD11.4B - AASTOCKS.com

INNOVENT BIO Issues Shrs at ~30% Premium to Takeda Pharma w/ Licensing Deal Involving USD11.4B - AASTOCKS.com

Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie TAK